METTL3 confers resistance to oxaliplatin by activating G6PD to enhance the pentose phosphate pathway [175] and leads to cisplatin resistance in OSCC, BRCA, ovarian serous cystadenocarcinoma (OV), and LUAD, suggesting the possibility of METTL3 inhibitor combined with platinum chemotherapy drugs [176–179]. Here, G6PD is linked to ovarian serous cystadenocarcinoma.